Kymera Therapeutics Inc’s recent filing unveils that its Chief Medical Officer Gollob Jared unloaded Company’s shares for reported $3.66 million on Oct 15 ’25. In the deal valued at $61.42 per share,59,576 shares were sold. As a result of this transaction, Gollob Jared now holds 109,992 shares worth roughly $6.69 million.
Then, Jared Gollob bought 59,576 shares, generating $3,470,898 in total proceeds.
Before that, Gollob Jared sold 3,114 shares. Kymera Therapeutics Inc shares valued at $186,840 were divested by the Chief Medical Officer at a price of $60.00 per share. As a result of the transaction, Gollob Jared now holds 118,359 shares, worth roughly $7.2 million.
B. Riley Securities reiterated its Kymera Therapeutics Inc [KYMR] rating to a Buy in a research note published on October 24, 2025; the price target was $80. A number of analysts have revised their coverage, including Mizuho’s analysts, who began to cover the stock in late October with a ‘”an Outperform”‘ rating. H.C. Wainwright also remained covering KYMR and reiterated its “Buy” recommendation on September 18, 2025. Barclays started covering the stock on September 17, 2025. It rated KYMR as “an Overweight”.
Price Performance Review of KYMR
On Monday, Kymera Therapeutics Inc [NASDAQ:KYMR] saw its stock jump 3.91% to $60.85. Over the last five days, the stock has gained 0.58%. Kymera Therapeutics Inc shares have risen nearly 24.79% since the year began. Nevertheless, the stocks have risen 51.26% over the past one year. While a 52-week high of $63.96 was reached on 10/16/25, a 52-week low of $19.44 was recorded on 04/09/25.
Levels Of Support And Resistance For KYMR Stock
The 24-hour chart illustrates a support level at 59.52, which if violated will result in even more drops to 58.20. On the upside, there is a resistance level at 61.75. A further resistance level may holdings at 62.66.
How much short interest is there in Kymera Therapeutics Inc?
A steep rise in short interest was recorded in Kymera Therapeutics Inc stocks on 2025-10-15, growing by 0.66 million shares to a total of 8.12 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 7.46 million shares. There was a rise of 8.16%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 16, 2025 when RBC Capital Mkts began covering the stock and recommended ‘”an Outperform”‘ rating along with a $70 price target.
